文献速递心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

钝性脑血管损伤:美国创伤外科协会前瞻性观察性血管损伤治疗(PROOVIT)多中心登记研究结果

Blunt cerebrovascular injuries: Outcomes from the American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment (PROOVIT) multicenter registry.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论在所有钝性脑血管损伤(BCVI)分级中,不给予抗血栓治疗与卒中和/或死亡风险升高相关(I/II级OR 4.66,III级OR 7.0,IV级OR 4.43),抗血小板药是出血高风险多发伤患者的有效替代。

该回顾性分析基于PROOVIT多中心登记研究,纳入971例BCVI,采用多因素分析识别BCVI相关卒中和死亡的预测因素,并按损伤分级和受累血管分层比较未治疗组与抗血小板药和/或抗凝药治疗组的不良结局风险。结果显示卒中发生率为7%,总死亡率为12%,两者均随BCVI分级升高而增加;抗血栓治疗与较低死亡率相关,且药物选择无显著影响。在控制协变量后,不给予抗血栓药在所有亚组均与卒中和/或死亡风险升高相关(I/II级OR 4.66,95%CI 2.48-8.75;III级OR 7.0,95%CI 2.01-24.5;IV级OR 4.43,95%CI 1.76-11.1)。作者认为,对于抗凝出血风险高的多发伤BCVI患者,抗血小板药是有效替代;鉴于初始创伤存活后发生BCVI相关卒中的患者死亡率为40%,不治疗可能不再是可行选择。

要点

  • 971例BCVI中卒中发生率7%、总死亡率12%,两者均随BCVI分级升高而增加。
  • 不给予抗血栓药与卒中和/或死亡风险升高相关:I/II级OR 4.66(95%CI 2.48-8.75),III级OR 7.0(95%CI 2.01-24.5),IV级OR 4.43(95%CI 1.76-11.1)。
  • 抗血栓治疗与较低死亡率相关,且抗血小板药与抗凝药之间的选择无显著影响。
  • 发生BCVI相关卒中的患者死亡风险增加4.2倍;初始创伤存活后发生BCVI相关卒中的患者死亡率为40%。
  • 死亡预测因素包括更严重的创伤、IV级损伤和发生卒中;卒中预测因素包括动脉闭塞、低血压和血管内介入。

适用人群与场景

  • 多发伤合并钝性脑血管损伤(BCVI)患者,来自PROOVIT多中心登记研究,共971例BCVI。
  • 按BCVI损伤分级(I/II级、III级、IV级)和受累血管进行分层分析。

诊断标准与关键阈值

  • BCVI损伤分级:I/II级、III级、IV级,卒中与死亡风险随分级升高而增加。

处置流程与药物剂量

  • 抗血栓治疗(抗血小板药和/或抗凝药)与较低死亡率相关,且药物选择无显著影响。
  • 对于抗凝出血风险高的多发伤BCVI患者,抗血小板药是有效替代(作者结论)。
  • 不给予抗血栓药在所有BCVI亚组均与卒中和/或死亡风险升高相关。

红旗征与不能漏的情况

  • 动脉闭塞、低血压和血管内介入是卒中的显著预测因素。
  • 更严重创伤、IV级损伤和发生卒中是死亡的预测因素。
  • 发生BCVI相关卒中的患者死亡风险增加4.2倍;初始创伤存活后发生BCVI相关卒中的患者死亡率为40%。

研究设计与关键结果

  • 研究类型:基于PROOVIT多中心登记研究的回顾性分析,纳入971例BCVI。
  • 卒中发生率7%,总死亡率12%,两者均随BCVI分级升高而增加。
  • 抗血栓治疗与较低死亡率相关,且药物选择无显著影响。
  • 不给予抗血栓药与卒中和/或死亡风险升高相关:I/II级OR 4.66(95%CI 2.48-8.75),III级OR 7.0(95%CI 2.01-24.5),IV级OR 4.43(95%CI 1.76-11.1),控制协变量后仍显著。
  • 死亡预测因素:更严重创伤、IV级损伤、发生卒中;卒中预测因素:动脉闭塞、低血压、血管内介入。
  • 发生BCVI相关卒中的患者死亡风险增加4.2倍;初始创伤存活后发生BCVI相关卒中的患者死亡率为40%。

证据类型、等级与局限

  • 证据类型:基于多中心登记研究的回顾性分析;证据等级:流行病学III级,治疗性IV级。
  • 局限:数据集缺乏评估抗血栓治疗时机或给药方案所需的粒度,限制了卒中预防策略的进一步分析。

对床旁实践的改变

  • 对于BCVI患者,不给予抗血栓药可能不再可行,因所有分级中不治疗均与卒中和/或死亡风险升高相关(作者结论)。
  • 对于抗凝出血风险高的多发伤BCVI患者,抗血小板药是有效替代(作者结论)。
  • 抗血栓治疗与较低死亡率相关,且药物选择无显著影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Administering antithrombotics (AT) to the multiply injured patient with blunt cerebrovascular injury (BCVI) requires a thoughtful assessment of the risk of stroke and death associated with nontreatment. Large, multicenter analysis of outcomes stratified by injury grade and vessel injured is needed to inform future recommendations.

METHODS: Nine hundred and seventy-one BCVIs were identified from the PROspective Vascular Injury Treatment registry in this retrospective analysis. Using multivariate analysis, we identified predictors of BCVI-related stroke and death. We then stratified these risks by injury grade and vessel injured. We compared the risk of adverse outcomes in the nontreatment group with those treated with antiplatelet agents and/or anticoagulants.

RESULTS: Stroke was identified in 7% of cases. Overall mortality was 12%. Both increased with increasing BCVI grade. Treatment with ATs was associated with lower mortality and was not significantly affected by the choice of agent. Withholding ATs was associated with an increased risk of stroke and/or death across all subgroups (Grade I/II: odds ratio [OR], 4.66; 95% confidence interval [CI], 2.48-8.75; Grade III: OR, 7.0; 95% CI, 2.01-24.5; Grade IV: OR, 4.43; 95% CI, 1.76-11.1) even after controlling for covariates. Predictors of death included more severe trauma, Grade IV injury, and the occurrence of stroke. Arterial occlusion, hypotension, and endovascular intervention were significant predictors of stroke. Patients that experienced a BCVI-related stroke were at a 4.2× increased risk of death. The data set lacked the granularity necessary to evaluate AT timing or dosing regimen, which limited further analysis of stroke prevention strategies.

CONCLUSION: Stroke and death remain significant risks for all BCVI grades regardless of the vessel injured. Antithrombotics represent the only management strategy that is consistently associated with a lower incidence of stroke and death in all BCVI categories. In the multi-injured BCVI patient with a high risk of bleeding on anticoagulation, antiplatelet agents are an efficacious alternative. Given the 40% mortality rate in patients who survived their initial trauma and developed a BCVI-related stroke, nontreatment may no longer be a viable option.

LEVEL OF EVIDENCE: Epidemiological III; Therapeutic IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Russo RM, Davidson AJ, Alam HB, et al. Blunt cerebrovascular injuries: Outcomes from the American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment (PROOVIT) multicenter registry. J Trauma Acute Care Surg. 2021. PMID: 34016922. doi:10.1097/TA.0000000000003127

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。